Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations

Slide collection

224,251-224,280 of 319,975

filter-aware
22
Includes detailed footnotes explaining valuation assumptions and share counts.Lionsgate | SPAC Presentation Deck | 35 slides · Lionsgate
Pitch deck Investment bank Beat · FinancialsLoop · Benchmark Gap1 hit
23
The slide illustrates a complex corporate spin-off/acquisition structure involving SPAC and PIPE investors.Lionsgate | SPAC Presentation Deck | 35 slides · Lionsgate
Pitch deck Investment bank Beat · FinancialsLoop · Benchmark Gap1 hit
24
Lionsgate | SPAC Presentation Deck | 35 slidesLionsgate | SPAC Presentation Deck | 35 slides · Lionsgate
Pitch deck Investment bank Beat · FinancialsLoop · Benchmark Gap1 hit
25
The chart highlights Lionsgate Studios as the final bar in green, suggesting a valuation gap relative to peers like Netflix and F1.Lionsgate | SPAC Presentation Deck | 35 slides · Lionsgate
Pitch deck Investment bank Beat · FinancialsLoop · Benchmark Gap1 hit
26
This is a standard financial disclosure slide found in investor presentations to define non-GAAP metrics.Lionsgate | SPAC Presentation Deck | 35 slides · Lionsgate
Pitch deck Investment bank Beat · Financials1 hit
27
Includes footnotes explaining the basis of estimates and definitions.Lionsgate | SPAC Presentation Deck | 35 slides · Lionsgate
Pitch deck Investment bank 1 hit
28
Includes detailed footnotes explaining the nature of adjustments and the use of 'NRE' (Not Reasonably Estimated) for future projections.Lionsgate | SPAC Presentation Deck | 35 slides · Lionsgate
Pitch deck Investment bank 1 hit
29
Contains a table reconciling operating income to Adjusted OIBDA with NRE (Not Reasonably Estimable) values.Lionsgate | SPAC Presentation Deck | 35 slides · Lionsgate
Pitch deck Investment bank 1 hit
30
Lionsgate | SPAC Presentation Deck | 35 slidesLionsgate | SPAC Presentation Deck | 35 slides · Lionsgate
Pitch deck Investment bank 1 hit
31
Standard legal disclaimer slide for Canadian securities offerings.Lionsgate | SPAC Presentation Deck | 35 slides · Lionsgate
Pitch deck Investment bank 1 hit
32
Lionsgate | SPAC Presentation Deck | 35 slidesLionsgate | SPAC Presentation Deck | 35 slides · Lionsgate
Pitch deck Investment bank 1 hit
33
Standard legal disclosure slide for a SPAC or M&A pitch deck.Lionsgate | SPAC Presentation Deck | 35 slides · Lionsgate
Pitch deck Investment bank 1 hit
34
Lionsgate | SPAC Presentation Deck | 35 slidesLionsgate | SPAC Presentation Deck | 35 slides · Lionsgate
Pitch deck Investment bank 1 hit
35
Lionsgate | SPAC Presentation Deck | 35 slidesLionsgate | SPAC Presentation Deck | 35 slides · Lionsgate
Pitch deck Investment bank 1 hit
01
Slide 1
Mainz Biomed NV | Investor Presentation Deck | 24 slidesMainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
02
Mainz Biomed NV | Investor Presentation Deck | 24 slidesMainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
03
The slide uses a 2x3 grid layout to present key company pillars.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations Loop · Golden Circle1 hit
04
The slide uses a comparison of logos to visually contrast the company's decentralized approach against centralized CLIA lab competitors.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
05
The slide uses a minimalist design with a halftone pattern and company branding.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
06
Includes a process flow diagram for the test journey and product imagery.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
07
The slide outlines the technical workflow from sample collection to diagnostic output.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
08
The slide uses a three-column layout to categorize achievements by strategic pillar.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
09
The slide features a minimalist design with a corporate logo and a halftone dot pattern.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
10
The slide uses a visual timeline/process flow to explain the biological progression of the disease.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
11
The slide uses data from a 2022 JNCI study to justify the clinical importance of AA detection sensitivity.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
12
The slide outlines a two-track diagnostic process (FIT and Genetic) converging into a proprietary algorithm.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations Beat · Solution1 hit
13
Mainz Biomed NV | Investor Presentation Deck | 24 slidesMainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
14
The table compares two distinct clinical trials (ColoFuture and eAArly DETECT) across key performance metrics.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
15
The slide uses two scatter plots to benchmark the company against competitors like Guardant Health, CellMax Life, and Cologuard.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations Beat · Market1 hit
16
Mainz Biomed NV | Investor Presentation Deck | 24 slidesMainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations 1 hit